{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:40:49Z","timestamp":1776418849465,"version":"3.51.2"},"reference-count":73,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["RSGI-16-163-01-CPHPS"],"award-info":[{"award-number":["RSGI-16-163-01-CPHPS"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189859"],"award-info":[{"award-number":["UG1CA189859"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA233180"],"award-info":[{"award-number":["UG1CA233180"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA233277"],"award-info":[{"award-number":["UG1CA233277"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189816"],"award-info":[{"award-number":["UG1CA189816"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA233270"],"award-info":[{"award-number":["UG1CA233270"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA233329"],"award-info":[{"award-number":["UG1CA233329"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA233373"],"award-info":[{"award-number":["UG1CA233373"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSGI-16-163-01-CPHPS"],"award-info":[{"award-number":["RSGI-16-163-01-CPHPS"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,27]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>To estimate the proportion and correlates of self-reported financial difficulty among patients with multiple myeloma (MM) or chronic lymphocytic leukaemia (CLL).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Setting<\/jats:title>\n<jats:p>Sixty-six US community and minority oncology practices affiliated with the National Cancer Institute Community Oncology Research Programme (NCORP).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Participants<\/jats:title>\n<jats:p>A total of 521 patients (=18 years) with MM or CLL consented and 416 responded to a survey (completion rate=79.8%). Respondents had a MM diagnosis (74.0%), an associate degree or higher (53.4%), were White (89.2%), insured (100%) and treated with clinician-administered drugs (68.0%).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Study design<\/jats:title>\n<jats:p>Observational, theoretical model and protocol-based patient survey administered between May 2019 and June 2020.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Primary and secondary outcome measures<\/jats:title>\n<jats:p>Financial difficulty was assessed using a single-item measure, the EORTC QLQC30: Has your physical condition or medical treatment caused you financial difficulties in the past year? and using an any-or-none composite measure of 22 items assessing financial difficulty, worries and the use of cost-coping strategies. Multivariable logistic regression models assessed the association of financial difficulty with diagnosis, socioeconomic and treatment characteristics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>About 16.8% reported experiencing financial difficulty using the single-item measure and 60.3% using the composite measure. Most frequently endorsed items in the composite measure were financial worry about having to pay large medical bills related to cancer and difficulty paying medical bills. Financial difficulty using the single-item measure was associated with having MM vs CLL (adjusted OR (aOR), 0.34; 95% CI, 0.13 to 0.84; p=0.02), having insurance other than Medicare (aOR, 2.53; 95% CI, 1.37 to 4.66; p=0.003), being non-White (aOR, 2.21; 95% CI, 1.04 to 4.72; p=0.04) and having a high school education or below (aOR, 0.36; 95% CI, 0.21 to 0.64; p=0.001). Financial difficulty using the composite measure was associated with having a high school education or below (aOR, 0.62; 95% CI, 0.41 to 0.94; p=0.03).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>US patients with MM and CLL report financial difficulty, especially those with low socio-economic status. Interventions are needed to mitigate patients financial difficulty.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>\n<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial \" xlink:href=\"NCT03870633\">NCT03870633<\/jats:ext-link>\n.\n<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2024-091769","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:00:19Z","timestamp":1749009619000},"page":"e091769","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Observational survey of financial difficulties among patients with multiple myeloma and chronic lymphocytic leukaemia treated at US community oncology clinics (Alliance A231602CD)"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03870633","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03870633","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4190-1839","authenticated-orcid":false,"given":"Rena M","family":"Conti","sequence":"first","affiliation":[{"name":"Boston University, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2245-3323","authenticated-orcid":false,"given":"Shaylene","family":"McCue","sequence":"additional","affiliation":[{"name":"Mayo Clinic Research Rochester, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7315-8499","authenticated-orcid":false,"given":"Travis","family":"Dockter","sequence":"additional","affiliation":[{"name":"Mayo Clinic Research Rochester, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8665-2867","authenticated-orcid":false,"given":"Heather","family":"Gunn","sequence":"additional","affiliation":[{"name":"Mayo Clinic Research Rochester, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-9196","authenticated-orcid":false,"given":"Stacie","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8968-4511","authenticated-orcid":false,"given":"Antonia","family":"Bennett","sequence":"additional","affiliation":[{"name":"Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce David","family":"Rapkin","sequence":"additional","affiliation":[{"name":"Epiemiology and Population Health, Albert Einsein College of Medicine, Bronx, New York, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Gracia","sequence":"additional","affiliation":[{"name":"University of Illinois Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley A","family":"Jazowski","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Behrens","sequence":"additional","affiliation":[{"name":"Iowa Wide Oncology Research Coalition, Des Moines, IA, Des Moines, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5897-8107","authenticated-orcid":false,"given":"Selina","family":"Chow","sequence":"additional","affiliation":[{"name":"Alliance Protocol Operations Office, University of Chicago, Chicago, IL, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niveditha","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Cancer Control Program, Alliance NCTN Foundation, Chicago, Illinois, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7462-8333","authenticated-orcid":false,"given":"Heather B","family":"Neuman","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-991X","authenticated-orcid":false,"given":"Elisa","family":"Weiss","sequence":"additional","affiliation":[{"name":"Leukemia and Lymphoma Society, Rye Brook, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2025071022150876000_15.6.e091769.1","unstructured":"Leukemia, Lymphoma Society . Updated data on blood cancers: facts 2020-2021. Leukemia & Lymphoma Society; 2021. Available: https:\/\/www.lls.org\/sites\/default\/files\/2021-08\/PS80%20FactsBook_2020_2021_FINAL.pdf"},{"key":"2025071022150876000_15.6.e091769.2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0031"},{"key":"2025071022150876000_15.6.e091769.3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2025071022150876000_15.6.e091769.4","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol"},{"key":"2025071022150876000_15.6.e091769.5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","article-title":"Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma","volume":"18","author":"Gupta","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025071022150876000_15.6.e091769.6","doi-asserted-by":"crossref","unstructured":"Fonseca R , Hagiwara M , Panjabi S , et al . Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US. Blood 2019;134. doi:10.1182\/blood-2019-123743","DOI":"10.1182\/blood-2019-123743"},{"key":"2025071022150876000_15.6.e091769.7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.874.874","article-title":"Multiple Myeloma Patient Experience with Financial Toxicity: Findings from the Cancer Experience Registry","volume":"126","author":"Buzaglo","year":"2015","journal-title":"Blood"},{"key":"2025071022150876000_15.6.e091769.8","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-178418","article-title":"Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patients Journey Using Qualitative Interview","volume":"142","author":"Park","year":"2023","journal-title":"Blood"},{"key":"2025071022150876000_15.6.e091769.9","first-page":"449","article-title":"A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma","volume":"25","author":"Hollmann","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2025071022150876000_15.6.e091769.10","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cam4.3855","article-title":"Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population","volume":"10","author":"Goyal","year":"2021","journal-title":"Cancer Med"},{"key":"2025071022150876000_15.6.e091769.11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133134","article-title":"Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?","volume":"13","author":"Smolej","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025071022150876000_15.6.e091769.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-12589-9","article-title":"Understanding the experience, treatment preferences and goals of people living with chronic lymphocytic leukemia (CLL) in Australia","volume":"24","author":"Fifer","year":"2024","journal-title":"BMC Cancer"},{"key":"2025071022150876000_15.6.e091769.13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1239.1239","article-title":"What Do Patients Prioritize in Selecting Chronic Lymphocytic Leukemia (CLL) Treatments?","volume":"128","author":"Mansfield","year":"2016","journal-title":"Blood"},{"key":"2025071022150876000_15.6.e091769.14","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.bbmt.2016.05.008","article-title":"Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation","volume":"22","author":"Abel","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025071022150876000_15.6.e091769.15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025071022150876000_15.6.e091769.16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/NCC.0b013e3182693522","article-title":"Personal financial effects of multiple myeloma and its treatment","volume":"36","author":"Goodwin","year":"2013","journal-title":"Cancer Nurs"},{"key":"2025071022150876000_15.6.e091769.17","unstructured":"PDQ Adult Treatment Editorial Board . Financial toxicity (financial distress) and cancer treatment (pdq). National Cancer Institute. Available: https:\/\/www.cancer.gov\/about-cancer\/managing-care\/track-care-costs\/financial-toxicity-pdq [Accessed 5 Nov 2021]."},{"key":"2025071022150876000_15.6.e091769.18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.16357","article-title":"Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US","volume":"4","author":"Bhattacharya","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025071022150876000_15.6.e091769.19","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1200\/JOP.18.00120","article-title":"financial toxicity in adults with cancer: adverse outcomes and noncompliance","volume":"14","author":"Knight","year":"2018","journal-title":"J Oncol Pract"},{"key":"2025071022150876000_15.6.e091769.20","doi-asserted-by":"publisher","DOI":"10.1257\/jep.29.1.139"},{"key":"2025071022150876000_15.6.e091769.21","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.3390\/curroncol29060305","article-title":"Patient Perceived Financial Burden in Haematological Malignancies: A Systematic Review","volume":"29","author":"Parker","year":"2022","journal-title":"Curr Oncol"},{"key":"2025071022150876000_15.6.e091769.22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01839-y"},{"key":"2025071022150876000_15.6.e091769.23","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.000971"},{"key":"2025071022150876000_15.6.e091769.24","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.000929"},{"key":"2025071022150876000_15.6.e091769.25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jamaoncol.2016.4850","article-title":"Mitigating Financial Toxicity Among US Patients With Cancer","volume":"3","author":"de Souza","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025071022150876000_15.6.e091769.26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamaoncol.2015.0423","article-title":"Addressing the Financial Burden of Cancer Treatment: From Copay to Cant Pay","volume":"1","author":"Shankaran","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025071022150876000_15.6.e091769.27","doi-asserted-by":"publisher","DOI":"10.1093\/tbm\/ibab091"},{"key":"2025071022150876000_15.6.e091769.28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab210"},{"key":"2025071022150876000_15.6.e091769.29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.74.5091"},{"key":"2025071022150876000_15.6.e091769.30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.18553\/jmcp.2018.24.1.56","article-title":"Recent Trends in Cost-Related Medication Nonadherence Among Cancer Survivors in the United States","volume":"24","author":"Lee","year":"2018","journal-title":"JMCP"},{"key":"2025071022150876000_15.6.e091769.31","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001406"},{"key":"2025071022150876000_15.6.e091769.32","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2021.01742"},{"key":"2025071022150876000_15.6.e091769.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01564"},{"key":"2025071022150876000_15.6.e091769.34","unstructured":"Lopes L , Kearney A , Montero A , et al . Health care debt in the u.s.: the broad consequences of medical and dental bills. KFF; 2022. Available: https:\/\/www.kff.org\/report-section\/kff-health-care-debt-survey-main-findings"},{"key":"2025071022150876000_15.6.e091769.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2008.05.012"},{"key":"2025071022150876000_15.6.e091769.36","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/s11606-019-05002-w","article-title":"Prevalence and Correlates of Medical Financial Hardship in the USA","volume":"34","author":"Yabroff","year":"2019","journal-title":"J Gen Intern Med"},{"key":"2025071022150876000_15.6.e091769.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04742-z"},{"key":"2025071022150876000_15.6.e091769.38","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7305"},{"key":"2025071022150876000_15.6.e091769.39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw205","article-title":"Financial Hardships Experienced by Cancer Survivors: A Systematic Review","volume":"109","author":"Altice","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2025071022150876000_15.6.e091769.40","unstructured":"NIH . The nci community oncology research program (ncorp). Available: https:\/\/ncorp.cancer.gov [Accessed 14 Dec 2022]."},{"key":"2025071022150876000_15.6.e091769.41","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001542"},{"key":"2025071022150876000_15.6.e091769.42","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025071022150876000_15.6.e091769.43","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902774765"},{"key":"2025071022150876000_15.6.e091769.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1249"},{"key":"2025071022150876000_15.6.e091769.45","doi-asserted-by":"publisher","DOI":"10.1207\/s15327906mbr0102_10"},{"key":"2025071022150876000_15.6.e091769.46","doi-asserted-by":"crossref","unstructured":"Rubin DB . Multiple Imputation for Nonresponse in Surveys . New York: John Wiley & Sons, 1987.","DOI":"10.1002\/9780470316696"},{"key":"2025071022150876000_15.6.e091769.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00297-2"},{"key":"2025071022150876000_15.6.e091769.48","unstructured":"Mazza GL , Enders CK . Handbook of Research Methods in Social and Personality Psychology. Cambridge University Press, 2014:62752."},{"key":"2025071022150876000_15.6.e091769.49","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21443"},{"key":"2025071022150876000_15.6.e091769.50","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-018-3185-8","article-title":"Revisiting out-of-pocket requirements: trends in spending, financial access barriers, and policy in ten high-income countries","volume":"18","author":"Rice","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2025071022150876000_15.6.e091769.51","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/1475-6773.12444","article-title":"High Out-of-Pocket Medical Spending among the Poor and Elderly in Nine Developed Countries","volume":"51","author":"Baird","year":"2016","journal-title":"Health Serv Res"},{"key":"2025071022150876000_15.6.e091769.52","unstructured":"WHO . Can people afford to pay for health care? new evidence on financial protection in europe. WHO Regional Office for Europe; 2019."},{"key":"2025071022150876000_15.6.e091769.53","doi-asserted-by":"crossref","unstructured":"OECD . 'Out-of-pocket medical expenditure', in health at a glance 2017: oecd indicators. OECD Publishing; 2017. Available: https:\/\/doi.org\/10.1787\/health_glance-2017-26-en","DOI":"10.1787\/health_glance-2017-26-en"},{"key":"2025071022150876000_15.6.e091769.54","unstructured":"OECD . Out of pocket spending: access to care and financial protection. 2019. Available: https:\/\/www.oecd.org\/en\/publications\/out-of-pocket-spending_fb38ab2e-en.html"},{"key":"2025071022150876000_15.6.e091769.55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz140"},{"key":"2025071022150876000_15.6.e091769.56","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-1157"},{"key":"2025071022150876000_15.6.e091769.57","doi-asserted-by":"crossref","unstructured":"de Moor JS , Mollica M , Sampson A , et al . Delivery of Financial Navigation Services Within National Cancer Institute-Designated Cancer Centers. JNCI Cancer Spectr 2021;5. doi:10.1093\/jncics\/pkab033","DOI":"10.1093\/jncics\/pkab033"},{"key":"2025071022150876000_15.6.e091769.58","first-page":"2047","article-title":"How cancer programs identify and address the financial burdens of rural cancer patients","volume":"30","author":"Petermann","year":"2022","journal-title":"Support Care Cancer"},{"key":"2025071022150876000_15.6.e091769.59","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00270"},{"key":"2025071022150876000_15.6.e091769.60","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.22.01799","article-title":"Financial Toxicity in Cancer Care: Implications for Clinical Care and Potential Practice Solutions","volume":"41","author":"Khan","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025071022150876000_15.6.e091769.61","doi-asserted-by":"crossref","unstructured":"Zhao J , Han X , Zheng Z , et al . Is Health Insurance Literacy Associated With Financial Hardship Among Cancer Survivors? Findings From a National Sample in the United States. JNCI Cancer Spectr 2019;3. doi:10.1093\/jncics\/pkz061","DOI":"10.1093\/jncics\/pkz061"},{"key":"2025071022150876000_15.6.e091769.62","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jamaoncol.2017.2148","article-title":"Out-of-Pocket Costs, Financial Distress, and Underinsurance in Cancer Care","volume":"3","author":"Chino","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025071022150876000_15.6.e091769.63","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1090","article-title":"Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance","volume":"4","author":"DiStefano","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2025071022150876000_15.6.e091769.64","unstructured":"Cubanski J , Neuman T , Damico A . Millions of people with Medicare will benefit from the new out-of-pocket drug spending cap over time. 2024. Available: https:\/\/www.kff.org\/medicare\/issue-brief\/millions-of-people-with-medicare-will-benefit-from-the-new-out-of-pocket-drug-spending-cap-over-time"},{"key":"2025071022150876000_15.6.e091769.65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2202726"},{"key":"2025071022150876000_15.6.e091769.66","doi-asserted-by":"crossref","unstructured":"Conti RM , Frank RG , Nichols LM . How Do Commercial Insurance Plans Fare Under Proposed Prescription Drug Price Regulation? JAMA Health Forum 2021;2. doi:10.1001\/jamahealthforum.2021.4242","DOI":"10.1001\/jamahealthforum.2021.4242"},{"key":"2025071022150876000_15.6.e091769.67","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21730"},{"key":"2025071022150876000_15.6.e091769.68","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/curroncol31020068","article-title":"Interventions to Mitigate Financial Toxicity in Adult Patients with Cancer in the United States: A Scoping Review","volume":"31","author":"Villalona","year":"2024","journal-title":"Curr Oncol"},{"key":"2025071022150876000_15.6.e091769.69","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35367"},{"key":"2025071022150876000_15.6.e091769.70","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/1078155217719585","article-title":"Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics","volume":"24","author":"Mitchell","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"2025071022150876000_15.6.e091769.71","first-page":"407","article-title":"The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients","volume":"23","author":"Zullig","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2025071022150876000_15.6.e091769.72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2017.07.004","article-title":"Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care","volume":"55","author":"Yezefski","year":"2018","journal-title":"Semin Hematol"},{"key":"2025071022150876000_15.6.e091769.73","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34220"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-091769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:25:29Z","timestamp":1753179929000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-091769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":73,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,3]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-091769"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-091769","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}